Home>>Signaling Pathways>> GPCR/G protein>> CXCR>>Zaprinast

Zaprinast

(Synonyms: 2-(2-丙氧苯基)-8-氮杂次黄嘌呤,M&B 22948) 目录号 : GC12909

A cGMP phosphodiesterase inhibitor

Zaprinast Chemical Structure

Cas No.:37762-06-4

规格 价格 库存 购买数量
10mg
¥381.00
现货
50mg
¥1,634.00
现货
100mg
¥2,903.00
现货
250mg
¥6,329.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

IC50: 0.15, 0.76, 12.0 and 29.0 μM for PDE6, 5, 11 and 9 respectively.

Zaprinast is a phosphodiesterase inhibitor with selection for PDE6, 5, 11 and 9[1].

Several isoforms of phosphodiesterases (PDEs) can mediate their action of the diverse cellular and behavioral responses to these second messengers. Accordingly, these responses are modulated by the rates of synthesis of cyclic nucleotides by cyclases as well as their degradation by PDEs to biologically inactive 59 monophosphate nucleosides.

In vitro: Zaprinast is a PDE5 and PDE6 inhibitor with inhibiting PDE9 at moderately high concentrations (29 mM) [1]. Indeed, it showed that inhibition of cGMP hydrolysis by infusion of zaprinast increases the effect of ANP on natriuresis with no causing deleterious drops in blood pressure. Because it was known that ANP receptors is localized within the glomerulus and inner medullary collecting ducts, to determine the cellular localization of PDE9 enzyme in kidney will be interesting. [2]. The enzyme displayed a high specificity for cGMP with binding sites for cGMP, and a sensitivity to zaprinast similar to smooth muscle PDE5, resulting in both enzymes were named cGMP-PDE. However, retinal cGMP-PDE was first distinguished as photoreceptor cGMP-PDE with being specifically distributed in the retina and having a higher Vmax and Km values than other cGMP-PDEs and being modulated by G protein. [3].

In vivo: So far, no study in vivo has been conducted.

Clinical trial: So far, no clinical study has been conducted.

References:
[1] Christensen and Torphy (1994) Isozyme-selective phosphodiesterase inhibitors as antiasthmatic agents.  Annu.Rep.Med.Chem. 29 185.
[2] Soderling SH, Bayuga SJ, Beavo JA.  Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem. 1998 Jun 19; 273(25):15553-8.
[3].  Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol Ther. 2006 Mar; 109 (3):366-98. Epub 2005 Aug 15.

Chemical Properties

Cas No. 37762-06-4 SDF
别名 2-(2-丙氧苯基)-8-氮杂次黄嘌呤,M&B 22948
化学名 5-(2-propoxyphenyl)-2H-[1,2,3]triazolo[4,5-d]pyrimidin-7(3H)-one
Canonical SMILES O=C1N=C(C2=CC=CC=C2OCCC)N=C3NNN=C31
分子式 C13H13N5O2 分子量 271.28
溶解度 DMF: 20 mg/ml,DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml,DMSO: 10 mg/ml 储存条件 Store at -20°C, protect from light, stored under nitrogen
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 3.6862 mL 18.4311 mL 36.8623 mL
5 mM 0.7372 mL 3.6862 mL 7.3725 mL
10 mM 0.3686 mL 1.8431 mL 3.6862 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置